Ted W. Love

Insider Reports History

Entity
Individual
Location
C/O Global Blood Therapeutics, Inc., 400 East Jamie Court, Suite 101, South San Francisco, CA
Signature
/s/ Jun Yoon, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Ted W. Love:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Royalty Pharma plc Director Class A Ordinary Shares 46.2K $1.4M $30.23 Jun 7, 2024 Direct
Structure Therapeutics Inc. Director Stock option (right to buy) 75K $598K $7.97 Aug 3, 2023 Direct
GILEAD SCIENCES, INC. Director Common Stock 2.82K $183K $64.92 May 8, 2024 Direct
Structure Therapeutics Inc. Director Share Option (right to buy) 33.6K Jun 25, 2024 Direct
GILEAD SCIENCES, INC. Director Non-qualified Stock Option (Right to Buy) 12.6K May 8, 2024 Direct
Global Blood Therapeutics, Inc. President and CEO, Director Common Stock 0 $46.99 Oct 5, 2022 By Daughter
Global Blood Therapeutics, Inc. President and CEO, Director Common Stock 0 $46.99 Oct 5, 2022 By Trust 1
Global Blood Therapeutics, Inc. President and CEO, Director Common Stock 0 $46.99 Oct 5, 2022 By Trust 2
Global Blood Therapeutics, Inc. President and CEO, Director Common Stock 0 $46.99 Oct 5, 2022 By Trust 3
Global Blood Therapeutics, Inc. President and CEO, Director Common Stock 0 $46.99 Oct 5, 2022 Direct
Global Blood Therapeutics, Inc. President and CEO, Director Restricted Stock Units 0 Oct 5, 2022 Direct
Global Blood Therapeutics, Inc. President and CEO, Director Stock Option (Right to Buy) 0 Oct 5, 2022 Direct
Seagen Inc. Director Common Stock 0 $229.00 Dec 14, 2023 Direct
Seagen Inc. Director Restricted Stock Units 0 $229.00 Dec 14, 2023 Direct
Seagen Inc. Director Stock Options (Right to Buy) 0 Dec 14, 2023 Direct

Insider Reports Filed by Ted W. Love

Symbol Company Period Transactions Value $ Form Type Date Filed Role
GPCR Structure Therapeutics Inc. Jun 25, 2024 1 $0 4 Jun 27, 2024 Director
RPRX Royalty Pharma plc Jun 7, 2024 1 $0 4 Jun 10, 2024 Director
GILD GILEAD SCIENCES, INC. May 8, 2024 2 $0 4 May 9, 2024 Director
GILD GILEAD SCIENCES, INC. Feb 2, 2024 2 $0 4 Feb 6, 2024 Director
GILD GILEAD SCIENCES, INC. Feb 1, 2024 0 $0 3 Feb 6, 2024 Director
SGEN Seagen Inc. Dec 14, 2023 6 -$974K 4 Dec 15, 2023 Director
GPCR Structure Therapeutics Inc. Aug 3, 2023 1 $0 4 Aug 4, 2023 Director
GPCR Structure Therapeutics Inc. Aug 3, 2023 0 $0 3 Aug 4, 2023 Director
RPRX Royalty Pharma plc Jun 23, 2023 1 $0 4 Jun 26, 2023 Director
SGEN Seagen Inc. May 31, 2023 1 $0 4 Jun 2, 2023 Director
GBT Global Blood Therapeutics, Inc. Oct 5, 2022 18 $0 4 Oct 6, 2022 President and CEO, Director
GBT Global Blood Therapeutics, Inc. Sep 27, 2022 6 $300K 4 Sep 29, 2022 President and CEO, Director
GBT Global Blood Therapeutics, Inc. Sep 1, 2022 5 -$627K 4 Sep 6, 2022 President and CEO, Director
GBT Global Blood Therapeutics, Inc. Aug 1, 2022 4 -$325K 4 Aug 3, 2022 President and CEO, Director
RPRX Royalty Pharma plc Jun 24, 2022 1 $0 4 Jun 24, 2022 Director
SGEN Seagen Inc. May 13, 2022 2 $0 4 May 17, 2022 Director
GBT Global Blood Therapeutics, Inc. Mar 1, 2022 7 -$100K 4 Mar 3, 2022 President and CEO, Director
GBT Global Blood Therapeutics, Inc. Feb 1, 2022 5 -$309K 4 Feb 3, 2022 President and CEO, Director
GBT Global Blood Therapeutics, Inc. Sep 1, 2021 3 -$140K 4 Sep 3, 2021 President and CEO, Director
GBT Global Blood Therapeutics, Inc. Aug 1, 2021 5 -$406K 4/A Sep 24, 2021 President and CEO, Director
RPRX Royalty Pharma plc Jun 25, 2021 1 $0 4 Jun 29, 2021 Director
SGEN Seagen Inc. May 14, 2021 2 $0 4 May 18, 2021 Director
GBT Global Blood Therapeutics, Inc. Jul 1, 2016 1 -$84.4K 4/A Jan 6, 2022 President and CEO, Director